Abstract
Organ transplant recipients are at risk of allograft rejection, and remain dependent on lifelong immunosuppressive agents, with the attendant risks of infections, cancers, and drug toxicities. Mesenchymal stromal cells (MSCs) have emerged as an alternative to the current pharmacologic immunosuppressive therapy as these cells are immune privileged and possess immunomodulatory properties. However, clinical data are incomplete regarding the efficacy of MSC therapy to control alloimmune response of the transplant recipients. Coordinated efforts should now be directed towards assays for monitoring anti-donor T cell response of MSC-treated patients to establish the pro-tolerogenic potential of MSC-based therapy.
Here, we describe two useful tools to monitor MSC-mediated immunomodulation: the assessment of T cell proliferation by carboxyfluorescein succinimidyl ester (CFSE) dilution assay and the evaluation of cytotoxic T lymphocyte (CTL)-mediated lysis of 51Cr-labeled target cells (cell-mediated lympholysis; CML) following mixed lymphocyte cultures of peripheral blood mononuclear cells (PBMCs) from kidney donors and transplant recipients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Casiraghi F, Perico N, Remuzzi G (2013) Mesenchymal stromal cells to promote solid organ transplantation tolerance. Curr Opin Organ Transplant 18:51–58
English K, Wood KJ (2013) Mesenchymal stromal cells in transplantation rejection and tolerance. Cold Spring Harb Perspect Med 3:a015560
Duffy MM, Ritter T, Ceredig R et al (2011) Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther 2:34
English K (2013) Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol 91:19–26
Le Blanc K, Mougiakakos D (2012) Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 12:383–396
Krampera M, Galipeau J, Shi Y et al (2013) Immunological characterization of multipotent mesenchymal stromal cells—the International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 15:1054–1061
Perico N, Casiraghi F, Introna M et al (2011) Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol 6:412–422
Casiraghi F, Azzollini N, Todeschini M et al (2012) Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am J Transplant 12:2373–2383
Koch M, Lehnhardt A, Hu X et al (2013) Isogeneic MSC application in a rat model of acute renal allograft rejection modulates immune response but does not prolong allograft survival. Transpl Immunol. doi:10.1016/j.trim.2013.08.004
Tan J, Wu W, Xu X et al (2012) Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 307:1169–1177
Reinders ME, de Fijter JW, Roelofs H et al (2013) Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. Stem Cells Transl Med 2:107–111
Perico N, Casiraghi F, Gotti E et al (2013) Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Transpl Int 26:867–878
Peng Y, Ke M, Xu L et al (2013) Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation 95:161–168
Acknowledgements
We greatly acknowledge Prof. Giuseppe Remuzzi and Dr. Norberto Perico for their suggestions and helpful discussion. This study has been partially supported by grants from Fondazione ART per la Ricerca sui Trapianti (Milan, Italy).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Rakha, A., Todeschini, M., Casiraghi, F. (2014). Assessment of Anti-donor T Cell Proliferation and Cytotoxic T Lymphocyte-Mediated Lympholysis in Living Donor Kidney Transplant Patients. In: Christ, B., Oerlecke, J., Stock, P. (eds) Animal Models for Stem Cell Therapy. Methods in Molecular Biology, vol 1213. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1453-1_29
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1453-1_29
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-1452-4
Online ISBN: 978-1-4939-1453-1
eBook Packages: Springer Protocols